Table 2. IC50 values of idelalisib and BYL719 treatment of MCC, B-ALL and multiple myeloma cell lines.
| cell lines | cancer type | MCPyV | IC50 idelalisib (µM) | IC50 Byl719 (µM) |
|---|---|---|---|---|
| MKL-1 | MCC | pos. | 29.6 | 11.5 |
| MKL-2 | MCC | pos. | 50.7 | 16.6 |
| WaGa | MCC | pos. | 63.1 | 2.2 |
| PeTa | MCC | pos. | 59.2 | 4.2 |
| MCC13 | MCC | neg. | 56.5 | 20.0 |
| MCC26 | MCC | neg. | 81.9 | 12.7 |
| REH | B-ALL | neg. | 3.1 | 1.2 |
| U266 | multiple myeloma | neg. | not deter. | n.d. |
Abbreviations: IC50= half maximal inhibitory concentration, B-ALL= B cell acute lymphoblastic leukemia pos.= positive; neg.= negative; not. deter. = not determinable adjusted in the manuscript, n.d.= not done.